Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.
Microarray patches (MAPs) are arrays of microneedles that stick to your skin like a bandage, offering a noninvasive mechanism for drug administration.
TAG delivered an intervention at the UN High-Level Meeting on Antimicrobial Resistance (AMR) Multistakeholder Hearing, calling on member states to incorporate drug-resistant TB (DR-TB) in the political declaration as a key component of AMR response.
On May 15, 2024, TAG hosted this webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.
Rifapentine, an off-patent drug that's been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.
TAG hosted this May 31 webinar on the growing pipeline of microarray patches (MAPs) for various infectious diseases treatment and immunization.
Follow along with one of our staff members on a typical day, and you'll see the difference you make as a TAG donor and partner.
1997 Michael Palm* Dr. David Ho 1998 Wafaa El-Sadr Dr. Mathilde Krim* 1999 Dr. Harold Varmus Irene Diamond* Spencer Cox* 2000 Tom Viola, BC/EFA Dr. Anthony S. Fauci Lynda M. Dee, Esq. 2001 Gregg Gonsalves Michael Cunningham Dr. Art Ammann*…
Save the Date: Monday, October 20, 2025 , when our Research in Action Awards return this fall! We'll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV). And until July 1, get tickets at our special-early bird rate!
Universal implementation of the best available treatment for drug-susceptible tuberculosis (TB) stands to cut 6.3 million years off total treatment by 2030, a new analysis released today by the 1/4/6x24 Campaign coalition has found.